REIT - Office
Compare Stocks
5 / 10Stock Comparison
ARE vs CTRE vs IIPR vs ONCO vs BXP
Revenue, margins, valuation, and 5-year total return — side by side.
REIT - Healthcare Facilities
REIT - Industrial
Biotechnology
REIT - Office
ARE vs CTRE vs IIPR vs ONCO vs BXP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | REIT - Office | REIT - Healthcare Facilities | REIT - Industrial | Biotechnology | REIT - Office |
| Market Cap | $7.89B | $8.82B | $1.62B | $1M | $9.43B |
| Revenue (TTM) | $2.90B | $468M | $263M | $815K | $3.48B |
| Net Income (TTM) | $-1.02B | $335M | $120M | $-14M | $277M |
| Gross Margin | 68.2% | 86.8% | 60.3% | 77.6% | 60.6% |
| Operating Margin | -42.8% | 69.1% | 46.7% | -21.9% | 42.3% |
| Forward P/E | 78.8x | 26.6x | 13.2x | — | 35.7x |
| Total Debt | $12.76B | $894M | $394M | $49K | $17.36B |
| Cash & Equiv. | $549M | $198M | $48M | $5M | $1.48B |
ARE vs CTRE vs IIPR vs ONCO vs BXP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Feb 22 | May 26 | Return |
|---|---|---|---|
| Alexandria Real Est… (ARE) | 100 | 24.1 | -75.9% |
| CareTrust REIT, Inc. (CTRE) | 100 | 225.8 | +125.8% |
| Innovative Industri… (IIPR) | 100 | 30.0 | -70.0% |
| Onconetix, Inc. (ONCO) | 100 | 0.0 | -100.0% |
| BXP, Inc. (BXP) | 100 | 48.6 | -51.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ARE vs CTRE vs IIPR vs ONCO vs BXP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ARE plays a supporting role in this comparison — it may shine differently against other peers.
CTRE carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 108.8%, EPS growth 96.3%, 3Y rev CAGR 36.5%
- 265.1% 10Y total return vs IIPR's 436.4%
- Lower volatility, beta 0.14, Low D/E 22.1%, current ratio 1.54x
- PEG 1.25 vs IIPR's 3.52
IIPR is the clearest fit if your priority is income & stability.
- Dividend streak 9 yrs, beta 0.92, yield 13.5%
ONCO is the #2 pick in this set and the best alternative if dividends is your priority.
- 30.9% yield, vs ARE's 11.7%
Among these 5 stocks, BXP doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 108.8% FFO/revenue growth vs ONCO's -67.7% | |
| Value | Lower P/E (26.6x vs 35.7x) | |
| Quality / Margins | 71.5% margin vs ONCO's -17.2% | |
| Stability / Safety | Beta 0.14 vs ONCO's 1.41 | |
| Dividends | 30.9% yield, vs ARE's 11.7% | |
| Momentum (1Y) | +40.3% vs ONCO's -98.6% | |
| Efficiency (ROA) | 6.7% ROA vs ONCO's -68.0%, ROIC 6.1% vs -32.8% |
ARE vs CTRE vs IIPR vs ONCO vs BXP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ARE vs CTRE vs IIPR vs ONCO vs BXP — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CTRE leads in 4 of 6 categories
ARE leads 0 • IIPR leads 0 • ONCO leads 0 • BXP leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
CTRE leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BXP is the larger business by revenue, generating $3.5B annually — 4270.8x ONCO's $815,371. CTRE is the more profitable business, keeping 71.5% of every revenue dollar as net income compared to ONCO's -17.2%. On growth, CTRE holds the edge at +99.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2.9B | $468M | $263M | $815,371 | $3.5B |
| EBITDAEarnings before interest/tax | $74M | $428M | $197M | -$18M | $2.4B |
| Net IncomeAfter-tax profit | -$1.0B | $335M | $120M | -$14M | $277M |
| Free Cash FlowCash after capex | $1.4B | $400M | $144M | -$10M | $690M |
| Gross MarginGross profit ÷ Revenue | +68.2% | +86.8% | +60.3% | +77.6% | +60.6% |
| Operating MarginEBIT ÷ Revenue | -42.8% | +69.1% | +46.7% | -21.9% | +42.3% |
| Net MarginNet income ÷ Revenue | -35.3% | +71.5% | +45.6% | -17.2% | +8.0% |
| FCF MarginFCF ÷ Revenue | +48.4% | +85.5% | +54.7% | -11.9% | +19.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -9.7% | +99.3% | -3.8% | -57.4% | +2.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +31.9% | +2.9% | -1.0% | +120.9% | +2.1% |
Valuation Metrics
Evenly matched — ARE and ONCO each lead in 2 of 7 comparable metrics.
Valuation Metrics
At 14.4x trailing earnings, IIPR trades at a 58% valuation discount to BXP's 34.2x P/E. Adjusting for growth (PEG ratio), CTRE offers better value at 1.19x vs IIPR's 3.85x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $7.9B | $8.8B | $1.6B | $1M | $9.4B |
| Enterprise ValueMkt cap + debt − cash | $20.1B | $9.5B | $2.0B | -$4M | $25.3B |
| Trailing P/EPrice ÷ TTM EPS | -5.40x | 25.17x | 14.40x | -0.09x | 34.17x |
| Forward P/EPrice ÷ next-FY EPS est. | 78.79x | 26.58x | 13.17x | — | 35.65x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.19x | 3.85x | — | — |
| EV / EBITDAEnterprise value multiple | 135.65x | 23.03x | 9.91x | — | 8.89x |
| Price / SalesMarket cap ÷ Revenue | 2.66x | 18.51x | 6.08x | 1.70x | 2.71x |
| Price / BookPrice ÷ Book value/share | 0.41x | 2.00x | 0.87x | 0.08x | 1.23x |
| Price / FCFMarket cap ÷ FCF | 5.58x | 23.27x | 9.26x | — | 13.68x |
Profitability & Efficiency
CTRE leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
CTRE delivers a 8.6% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-190 for ONCO. ONCO carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to BXP's 2.26x. On the Piotroski fundamental quality scale (0–9), BXP scores 6/9 vs IIPR's 4/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -5.0% | +8.6% | +6.4% | -189.8% | +3.6% |
| ROA (TTM)Return on assets | -2.9% | +6.7% | +5.1% | -68.0% | +1.1% |
| ROICReturn on invested capital | -2.7% | +6.1% | +4.3% | -32.8% | +6.1% |
| ROCEReturn on capital employed | -3.6% | +7.7% | +5.8% | -49.4% | +7.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 | 4 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.67x | 0.22x | 0.21x | 0.00x | 2.26x |
| Net DebtTotal debt minus cash | $12.2B | $696M | $346M | -$5M | $15.9B |
| Cash & Equiv.Liquid assets | $549M | $198M | $48M | $5M | $1.5B |
| Total DebtShort + long-term debt | $12.8B | $894M | $394M | $48,774 | $17.4B |
| Interest CoverageEBIT ÷ Interest expense | -4.37x | 8.44x | 6.67x | -26.95x | 1.59x |
Total Returns (Dividends Reinvested)
CTRE leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CTRE five years ago would be worth $19,660 today (with dividends reinvested), compared to $0 for ONCO. Over the past 12 months, CTRE leads with a +40.3% total return vs ONCO's -98.6%. The 3-year compound annual growth rate (CAGR) favors CTRE at 29.6% vs ONCO's -97.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -5.5% | +9.9% | +18.3% | -95.0% | -11.3% |
| 1-Year ReturnPast 12 months | -30.9% | +40.3% | +20.3% | -98.6% | -2.4% |
| 3-Year ReturnCumulative with dividends | -51.0% | +117.8% | +14.1% | -100.0% | +38.2% |
| 5-Year ReturnCumulative with dividends | -61.1% | +96.6% | -50.0% | -100.0% | -27.7% |
| 10-Year ReturnCumulative with dividends | -8.6% | +265.1% | +436.4% | -100.0% | -27.8% |
| CAGR (3Y)Annualised 3-year return | -21.2% | +29.6% | +4.5% | -97.2% | +11.4% |
Risk & Volatility
CTRE leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CTRE is the less volatile stock with a 0.14 beta — it tends to amplify market swings less than ONCO's 1.41 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CTRE currently trades 94.7% from its 52-week high vs ONCO's 0.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.95x | 0.14x | 0.92x | 1.41x | 0.96x |
| 52-Week HighHighest price in past year | $88.24 | $41.72 | $61.40 | $74.30 | $79.33 |
| 52-Week LowLowest price in past year | $39.41 | $27.72 | $44.58 | $0.37 | $49.72 |
| % of 52W HighCurrent price vs 52-week peak | +51.7% | +94.7% | +92.2% | +0.5% | +75.0% |
| RSI (14)Momentum oscillator 0–100 | 52.2 | 54.5 | 59.3 | 28.8 | 63.7 |
| Avg Volume (50D)Average daily shares traded | 2.5M | 2.5M | 303K | 9.4M | 2.4M |
Analyst Outlook
Evenly matched — ARE and ONCO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ARE as "Hold", CTRE as "Buy", IIPR as "Hold", BXP as "Buy". Consensus price targets imply 21.3% upside for BXP (target: $72) vs -22.3% for IIPR (target: $44). For income investors, ONCO offers the higher dividend yield at 30.89% vs CTRE's 3.22%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Hold | — | Buy |
| Price TargetConsensus 12-month target | $55.00 | $42.50 | $44.00 | — | $72.10 |
| # AnalystsCovering analysts | 24 | 19 | 11 | — | 42 |
| Dividend YieldAnnual dividend ÷ price | +11.7% | +3.2% | +13.5% | +30.9% | +6.8% |
| Dividend StreakConsecutive years of raises | 15 | 2 | 9 | 0 | 0 |
| Dividend / ShareAnnual DPS | $5.35 | $1.27 | $7.62 | $0.12 | $4.05 |
| Buyback YieldShare repurchases ÷ mkt cap | +2.6% | +0.0% | +1.2% | 0.0% | 0.0% |
CTRE leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
ARE vs CTRE vs IIPR vs ONCO vs BXP: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ARE or CTRE or IIPR or ONCO or BXP a better buy right now?
For growth investors, CareTrust REIT, Inc.
(CTRE) is the stronger pick with 108. 8% revenue growth year-over-year, versus -67. 7% for Onconetix, Inc. (ONCO). Innovative Industrial Properties, Inc. (IIPR) offers the better valuation at 14. 4x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate CareTrust REIT, Inc. (CTRE) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ARE or CTRE or IIPR or ONCO or BXP?
On trailing P/E, Innovative Industrial Properties, Inc.
(IIPR) is the cheapest at 14. 4x versus BXP, Inc. at 34. 2x. On forward P/E, Innovative Industrial Properties, Inc. is actually cheaper at 13. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: CareTrust REIT, Inc. wins at 1. 25x versus Innovative Industrial Properties, Inc. 's 3. 52x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — ARE or CTRE or IIPR or ONCO or BXP?
Over the past 5 years, CareTrust REIT, Inc.
(CTRE) delivered a total return of +96. 6%, compared to -100. 0% for Onconetix, Inc. (ONCO). Over 10 years, the gap is even starker: IIPR returned +436. 4% versus ONCO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ARE or CTRE or IIPR or ONCO or BXP?
By beta (market sensitivity over 5 years), CareTrust REIT, Inc.
(CTRE) is the lower-risk stock at 0. 14β versus Onconetix, Inc. 's 1. 41β — meaning ONCO is approximately 933% more volatile than CTRE relative to the S&P 500. On balance sheet safety, Onconetix, Inc. (ONCO) carries a lower debt/equity ratio of 0% versus 2% for BXP, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ARE or CTRE or IIPR or ONCO or BXP?
By revenue growth (latest reported year), CareTrust REIT, Inc.
(CTRE) is pulling ahead at 108. 8% versus -67. 7% for Onconetix, Inc. (ONCO). On earnings-per-share growth, the picture is similar: BXP, Inc. grew EPS 1833% year-over-year, compared to -568. 9% for Alexandria Real Estate Equities, Inc.. Over a 3-year CAGR, CTRE leads at 36. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ARE or CTRE or IIPR or ONCO or BXP?
CareTrust REIT, Inc.
(CTRE) is the more profitable company, earning 67. 3% net margin versus -1721. 0% for Onconetix, Inc. — meaning it keeps 67. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CTRE leads at 67. 2% versus -778. 2% for ONCO. At the gross margin level — before operating expenses — IIPR leads at 88. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ARE or CTRE or IIPR or ONCO or BXP more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, CareTrust REIT, Inc. (CTRE) is the more undervalued stock at a PEG of 1. 25x versus Innovative Industrial Properties, Inc. 's 3. 52x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Innovative Industrial Properties, Inc. (IIPR) trades at 13. 2x forward P/E versus 78. 8x for Alexandria Real Estate Equities, Inc. — 65. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BXP: 21. 3% to $72. 10.
08Which pays a better dividend — ARE or CTRE or IIPR or ONCO or BXP?
All stocks in this comparison pay dividends.
Onconetix, Inc. (ONCO) offers the highest yield at 30. 9%, versus 3. 2% for CareTrust REIT, Inc. (CTRE).
09Is ARE or CTRE or IIPR or ONCO or BXP better for a retirement portfolio?
For long-horizon retirement investors, CareTrust REIT, Inc.
(CTRE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 14), 3. 2% yield, +265. 1% 10Y return). Both have compounded well over 10 years (CTRE: +265. 1%, ONCO: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ARE and CTRE and IIPR and ONCO and BXP?
These companies operate in different sectors (ARE (Real Estate) and CTRE (Real Estate) and IIPR (Real Estate) and ONCO (Healthcare) and BXP (Real Estate)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ARE is a small-cap income-oriented stock; CTRE is a small-cap high-growth stock; IIPR is a small-cap deep-value stock; ONCO is a small-cap income-oriented stock; BXP is a small-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.